DIA: Driving Insights to Action
Science:Life Sciences
New horizons opened by personalized (or precision) medicine are also opportunities for combination products, explains Bill Zeruld, a senior Business Development–Digital Strategy executive with Otsuka America Pharmaceuticals, Inc., and a member of the program committee for DIA’s Combination Products Conference. “It’s an exciting time for industry because you start to now have the power of the traditional medicines and traditional medical devices enhanced with the power of digital technology and the underlying data that supports those technologies,” he explains.
Novel Approaches to PV Collaboration
Advancing the Science of Study Endpoints
Analyzing Innovation’s Progress in Gottlieb Era
Comparing Generic Safety Profile with Branded Cousin
Defining Unmet Need Critical to Determining Value
Triple-A RWE: Adequate Data, Appropriate Designs, Actionable Evidence
US REMS Requirements for NDAs and BLAs
Epoietin Biosimilars: Qualitative Study of Patients' Views
Disparities Between FDA/EMA Review Processes
DIA Japan's Focus in Fall 2018
FDA Leadership on Future Biologics and EMA/FDA Cooperation
Global Perspectives on Patient Engagement
DIA Board Chair Discusses DIA Now and Digital Tomorrow
Integrating Genetic Medicine into Clinical Care
Regulatory Landscape of Drug-Device Combination Products
Value-Based Assessment & Contracting: What Needs to Be Done?
Block Chain, AI, Internet of Things: Future of PharmaTech?
“My Voice Needed to Be Heard”
IMEDS Collaboration Builds Upon Sentinel Surveillance
Crafting Sound Medical Affairs Professionals
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Speaking of Psychology
COMPLEXITY